Axsome Therapeutics, Inc. (AXSM)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 74.80 |
| Open | 75.00 |
| Bid | 75.66 x 100 |
| Ask | 76.24 x 200 |
| Day's range | 73.31 - 77.98 |
| 52-week range | 55.02 - 98.40 |
| Volume | |
| Avg. volume | 730,240 |
| Market cap | 3.607B |
| Beta (5Y monthly) | 1.10 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.27 |
| Earnings date | 05 Aug 2024 - 09 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 124.67 |
- Thomson Reuters StreetEvents
Q1 2024 Axsome Therapeutics Inc Earnings Call
Q1 2024 Axsome Therapeutics Inc Earnings Call
GlobeNewswireAxsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Total 1Q 2024 net product revenue of $75.0 million, representing 160% year-over-year growth Auvelity® 1Q 2024 net product sales of $53.4 million, representing 240% year-over-year growth Sunosi® 1Q 2024 net product revenue of $21.6 million representing 64% year-over-year growth Contract executed with second large group purchasing organization (GPO) for potential coverage of Auvelity Positive pivotal Phase 3 trial results of AXS-12 in narcolepsy announced Topline results of ADVANCE-2 Phase 3 trial
ZacksShould You Buy Axsome Therapeutics (AXSM) Ahead of Earnings?
Axsome Therapeutics (AXSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
© 2024 Yahoo. All rights reserved.